Osteoporosis in liver cirrhosis;Osteoporosis en la cirrosis hepática

Gastroenterologia y Hepatologia

Volumn 35, Issue 6, 2012, Pages 411-420

  Guañabens, Núria ^a   Parés, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bisphosphonates; Bone mineral density; Chronic cholestasis; Fractures; Primary biliary cirrhosis; Vitamin D

Indexed keywords

ALCOHOL; BILE ACID; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IRON; VITAMIN D;

ARTICLE; BONE ATROPHY; BONE MASS; CHOLESTASIS; DRUG SAFETY; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NUTRITIONAL STATUS; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; POSTOPERATIVE PERIOD; VITAMIN SUPPLEMENTATION;

BILE ACIDS AND SALTS; BILIRUBIN; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CELLS, CULTURED; CYTOKINES; ESTROGENS; FEMALE; FORECASTING; FRACTURES, SPONTANEOUS; HUMANS; LIVER CIRRHOSIS; MALE; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; PREVALENCE; VITAMIN D;

EID: 84862898469     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2012.01.017     Document Type: Article

References (62)

1. Compston J.E. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut 1986, 27:1073-1090.
2. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005, 115:3318-3325.
3. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
4. Pares A., Guañabens N. Treatment of bone disorders in liver disease. J Hepatol 2006, 45:445-453.
5. Guañabens N., Cerda D., Monegal A., Pons F., Caballeria L., Peris P., et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010, 138:2348-2356.
6. Collier J. Bone disorders in chronic liver disease. Hepatology 2007, 46:1271-1278.
7. Pares A., Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008, 12:407-424.
8. Bonkovsky H.L., Hawkins M., Steinberg K., Hersh T., Galambos J.T., Henderson J.M., et al. Prevalence and prediction of osteopenia in chronic liver disease 2. Hepatology 1990, 12:273-280.
9. Sinigaglia L., Fargion S., Fracanzani A.L., Binelli L., Battafarano N., Varenna M., et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 1997, 24:1809-1813.
10. Guggenbuhl P., Deugnier Y., Boisdet J.F., Rolland Y., Perdriger A., Pawlotsky Y., et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005, 16:1809-1814.
11. Valenti L., Varenna M., Fracanzani A.L., Rossi V., Fargion S., Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 2009, 20:549-555.
12. Olsson R., Johansson C., Lindstedt G., Mellstrom D. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 1994, 29:753-756.
13. Guañabens N., Monegal A. Bone disease after liver transplantation 2005, 271-285. Elsevier, Barcelona. J. Compston, E. Shane (Eds.).
14. Guichelaar M.M., Kendall R., Malinchoc M., Hay J.E. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006, 12:1390-1402.
15. Monegal A., Navasa M., Guañabens N., Peris P., Pons F., Martinez de Osaba M.J., et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001, 12:484-492.
16. Navasa M., Monegal A., Guañabens N., Peris P., Rimola A., Munoz-Gomez J., et al. Bone fractures in liver transplant patients. Br J Rheumatol 1994, 33:52-55.
17. Compston J.E. Osteoporosis after liver transplantation. Liver Transpl 2003, 9:321-330.
18. Guañabens N., Pares A., Marinoso L., Brancos M.A., Piera C., Serrano S., et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990, 85:1356-1362.
19. Stellon A.J., Webb A., Compston J., Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987, 7:137-142.
20. Guichelaar M.M., Malinchoc M., Sibonga J.D., Clarke B.L., Hay J.E. Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res 2003, 18:2190-2199.
21. Guañabens N., Pares A., Alvarez L., Martinez de Osaba M.J., Monegal A., Peris P., et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998, 13:731-738.
22. Gallego-Rojo F.J., Gonzalez-Calvin J.L., Munoz-Torres M., Mundi J.L., Fernandez-Perez R., Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28:695-699.
23. Cemborain A., Castilla-Cortazar I., Garcia M., Quiroga J., Muguerza B., Picardi A., et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998, 28:122-131.
24. Kawelke N., Bentmann A., Hackl N., Hager H.D., Feick P., Geursen A., et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res 2008, 23:1278-1286.
25. Janes C.H., Dickson E.R., Okazaki R., Bonde S., McDonagh A.F., Riggs B.L. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995, 95:2581-2586.
26. Ruiz-Gaspa S, Martinez-Ferrer A, Enjuanes A, Peris P, Martinez de Osaba MJ, Alvarez L, et al. High bilirubin reduces cell survival and differentiation of primary human osteoblasts. Is this effect applicable to the serum of chronic cholestatic patients? [Abstract]. J Hepatol. 2010; 52: s214-5.
27. Smith D.L., Shire N.J., Watts N.B., Schmitter T., Szabo G., Zucker S.D. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. J Clin Densitom 2006, 9:105-113.
28. Minuk G.Y., Greenberg R., Uhanova J., Hawkins K., Leslie W.D. Bone mineral densities in individuals with Gilbert's syndrome: a cross-sectional, case-control pilot study. Can J Gastroenterol 2009, 23:431-436.
29. Ruiz-Gaspa S., Guañabens N., Enjuanes A., Peris P., Martinez-Ferrer A., de Osaba M.J., et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010, 40:25-34.
30. Peris P., Pares A., Guañabens N., Pons F., Martinez de Osaba M.J., Caballeria J., et al. Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol 1992, 27:619-625.
31. Diamond T., Stiel D., Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?. Ann Intern Med 1989, 110:430-436.
32. Cuthbert J.A., Pak C.Y., Zerwekh J.E., Glass K.D., Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984, 4:1-8.
33. Hodgson S.F., Dickson E.R., Eastell R., Eriksen E.F., Bryant S.C., Riggs B.L. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993, 14:819-827.
34. McCaughan G.W., Feller R.B. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 1994, 12:223-231.
35. Szalay F., Hegedus D., Lakatos P.L., Tornai I., Bajnok E., Dunkel K., et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 2003, 38:395-400.
36. Guañabens N., Enjuanes A., Alvarez L., Peris P., Caballeria L., Jesus Martinez de O.M., et al. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J Bone Miner Metab 2009, 27:347-354.
37. Nakchbandi I.A., van der Merwe S.W. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 2009, 6:660-670.
38. Gonzalez-Calvin J.L., Mundi J.L., Casado-Caballero F.J., Abadia A.C., Martin-Ibanez J.J. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J Clin Endocrinol Metab 2009, 94:4844-4850.
39. Diamond T., Stiel D., Lunzer M., Wilkinson M., Posen S. Ethanol reduces bone formation and may cause osteoporosis. Am J Med 1989, 86:282-288.
40. Hodges SJ, Rigney E, Eastell R, Lee A, Gleeson D. Undercarboxylation of serum osteocalcin in primary biliary cirrhosis (PBC); Reversal by vitamin K1 [Abstract]. Hepatology. 2000;32:309A.
41. Pares A., Guañabens N., Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005, 17:311-315.
42. Springer J.E., Cole D.E., Rubin L.A., Cauch-Dudek K., Harewood L., Evrovski J., et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000, 118:145-151.
43. Pares A., Guañabens N., Alvarez L., de Osaba M.J., Oriola J., Pons F., et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001, 33:554-560.
44. Lakatos L.P., Bajnok E., Hegedus D., Toth T., Lakatos P., Szalay F. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002, 14:733-740.
45. Guañabens N., Monegal A., Muxi A., Martinez-Ferrer A., Reyes R., Caballeria J., et al. Patients with cirrhosis and ascites have false values of bone density: Implications for the diagnosis of osteoporosis. Osteoporos Int 2012, 23:1481-1487.
46. Leslie W.D., Bernstein C.N., Leboff M.S. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003, 125:941-966.
47. Guañabens N., Pares A., Monegal A., Peris P., Pons F., Alvarez L., et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997, 113:219-224.
48. Wolfhagen F.H., van Buuren H.R., den Ouden J.W., Hop W.C., van Leeuwen J.P., Schalm S.W., et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997, 26:325-330.
49. Lindor K.D., Jorgensen R.A., Tiegs R.D., Khosla S., Dickson E.R. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000, 33:878-882.
50. Guañabens N., Pares A., Ros I., Alvarez L., Pons F., Caballeria L., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003, 98:2268-2274.
51. Zein C.O., Jorgensen R.A., Clarke B., Wenger D.E., Keach J.C., Angulo P., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005, 42:762-771.
52. Guañabens N., Vazquez I., Alvarez L., Pons F., Caballeria L., Cerda D., et al. Alendronate 70mg once-weekly is more effective and has a better tolerability than alendronate 10mg daily in the treatment of osteopenia aassociated with primary biliary cirrhosis [Abstract]. J Bone Miner Res 2005, 20:S279.
53. Millonig G., Graziadei I.W., Eichler D., Pfeiffer K.P., Finkenstedt G., Muehllechner P., et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005, 11:960-966.
54. Atamaz F., Hepguler S., Akyildiz M., Karasu Z., Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int 2006, 17:942-949.
55. Ninkovic M., Love S., Tom B.D., Bearcroft P.W., Alexander G.J., Compston J.E. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 2002, 37:93-100.
56. Dodidou P., Bruckner T., Hosch S., Haass M., Klar E., Sauer P., et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 2003, 14:82-89.
57. Monegal A., Guañabens N., Suarez M.J., Suarez F., Clemente G., Garcia-Gonzalez M., et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009, 22:198-206.
58. Crawford B.A., Kam C., Pavlovic J., Byth K., Handelsman D.J., Angus P.W., et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144:239-248.
59. Misof B.M., Bodingbauer M., Roschger P., Wekerle T., Pakrah B., Haas M., et al. Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int 2008, 83:167-175.
60. Diamond T., Stiel D., Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991, 6:39-43.
61. Levy C., Harnois D.M., Angulo P., Jorgensen R., Lindor K.D. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005, 25:117-121.
62. Dresner-Pollak R., Gabet Y., Steimatzky A., Hamdani G., Bab I., Ackerman Z., et al. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology 2008, 134:259-267.